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Introduction
Gap junctions are intercellular structures that facilitate direct 
communication among adjacent cells by allowing passage of 
ions and small metabolites (White and Paul, 1999; Saez et al., 
2003; Sohl and Willecke, 2004; Laird, 2006). Vertebrate gap 
junctions, composed of integral membrane proteins encoded by 
the 21-member connexin gene family, are critically important in 
regulating embryonic development, coordinated contraction of 
excitable cells, tissue homeostasis, normal cell growth, and dif-
ferentiation (Saez et al., 2003; Sohl and Willecke, 2004). Their 
functional importance has been shown by the linkage of con-
nexin mutations to deafness and several diseases (Bergoffen 
et al., 1993; Gong et al., 1997; Kelsell et al., 1997; Laird, 2006) 
including oculodentodigital dysplasia, a disease linked to con-
nexin43 (Cx43) mutations that can cause atrioseptal defects and 
arrhythmias (Paznekas et al., 2003).
Cx43, the most ubiquitously expressed connexin, is dif-
ferentially phosphorylated at a dozen or more serine residues 
throughout its life cycle (Lampe and Lau, 2004; Solan and 
Lampe, 2005). Regulation of Cx43 may occur at many different 
stages, including the oligomerization of six connexin proteins 
into a hemi-channel or connexon, connexon transport to the 
plasma membrane, intercellular docking of connexons to form 
intercellular channels, condensation of hundreds to thousands 
of these channels into paracrystalline arrays (termed gap junc-
tional plaques), gap junction channel gating, and turnover of 
plaques. There is correlative evidence that gap junctional com-
munication and Cx43 levels may be controlled by phosphory-
lation of Cx43 at many of these steps; however, the mechanisms 
underlying these events have remained elusive.
Cx43 from cultured cells commonly demonstrates multiple 
electrophoretic isoforms when analyzed by SDS-PAGE: a faster 
migrating form (sometimes referred to as P0 or NP) that includes 
the nonphosphorylated isoform, and multiple slower migrating 
forms (sometimes termed P1 and P2) (Musil and Goodenough, 
1991). After alkaline phosphatase treatment in vitro, the phos-
phorylated species collapse to the fastest migrating form, sug-
gesting that phosphorylation is the primary covalent modifi  cation 
resulting in the conformational change detected in SDS-PAGE 
analysis. Studies investigating phosphorylation in normal rat kid-
ney (NRK) cells showed that Cx43 acquired resistance to Triton 
X-100 and was found in gap junction plaques when it had been 
phosphorylated to the P2 isoform (Musil and Goodenough, 1991). 
P2 formation requires phosphorylation at S325, S328, and/or 
S330 (Lampe et al., 2006). Myocardial ischemia leads to unspeci-
fi  ed Cx43 “dephosphorylation” events and loss of localization to 
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hosphorylation at unspeciﬁ  ed sites is known to reg-
ulate the life cycle (assembly, gating, and turnover) 
of the gap junction protein, Cx43. In this paper, we 
show that Cx43 is phosphorylated on S365 in cultured 
cells and heart tissue. Nuclear magnetic resonance structural 
studies of the C-terminal region of Cx43 with an S365D 
mutation indicate that it forms a different stable conforma-
tion than unphosphorylated wild-type Cx43. Immuno-
labeling with an antibody speciﬁ  c for Cx43 phosphorylated 
at S365 shows staining on gap junction structures in heart 
tissue that is lost upon hypoxia when Cx43 is no longer 
speciﬁ  cally localized to the intercalated disk. Efﬁ  cient phos-
phorylation at S368, an important Cx43 channel regu-
latory event that increases during ischemia or PKC activation, 
depends on S365 being unphosphorylated. Thus, phos-
phorylation at S365 can serve a “gatekeeper” function 
that may represent a mechanism to protect cells from isch-
emia and phorbol ester-induced down-regulation of chan-
nel conductance.
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the intercalated disk, which likely contribute to contractile failure 
and arrhythmias (Beardslee et al., 2000; Schulz et al., 2003). 
Thus, uncharacterized phosphorylation events have been corre-
lated with changes in Cx43 localization, inclusion in gap junction 
structures, and acquisition of Triton X-100 insolubility.
We have previously shown that Cx43 is phosphorylated at 
S368 in basal keratinocytes near the edge of a human wound, in 
heart tissue upon hypoxia, during S and G2/M phases of the cell 
cycle, and upon treatment with phorbol esters (Lampe et al., 1998; 
Solan et al., 2003; Richards et al., 2004; Ek-Vitorin et al., 2006). 
Phosphorylation at S368 reduces the conductivity of the gap 
junction channel, potentially causing the formation of communi-
cation compartments (Ek-Vitorin et al., 2006). In this paper, 
we show that Cx43 is phosphorylated on S365 in homeostatic 
cells and that this event is required for formation of the P1 iso-
form. Structural studies of the C-terminal region of Cx43 with a 
S365D mutation, intended to mimic phosphorylation, indicate 
that this change generates a different stable conformation than 
unphosphorylated, wild-type Cx43. Preparation and use of an an-
tibody specifi  c for Cx43 only when it is phosphorylated at S365 
showed that this phosphorylation event occurs on Cx43 present 
specifi  cally in gap junction structures in cultured cells and in 
heart tissue. Phosphorylation at S365 was constitutive in heart 
tissue but absent during hypoxia when Cx43 loses its specifi  c 
Figure 1.  LC/ESI MS/MS of a phosphory-
lated peptide from Cx43. A gel band enriched 
for phosphorylated Cx43 was digested with 
trypsin and analyzed with an LTQ-FT mass 
spectrometer. (A) Chromatographic elution of 
the tryptic peptide mixture into the mass spec-
trometer revealed a peak at 26.02 min that 
contained a triply charged monoisotopic ion 
species (m/z 742.04611) that was suspected 
to be the peptide V347 to R366 of Cx43 con-
taining a single phosphate group. (B) Tandem 
mass spectrometry (MS2) of this precursor ion 
species resulted in a fragmentation spectrum 
dominated by ion species m/z 710.5 that indi-
cates the neutral loss of phosphoric acid (m/z 
31.5) from the precursor. It is important to note 
that the deviation of m/z 1.2 from the ex-
pected value of m/z 32.7 for the neutral loss 
of a phosphate group is a result of the error as-
sociated with subtracting a low mass accuracy, 
average m/z value in B from the high mass 
accuracy, monoisotopic value in A. The differ-
ence in the two types of measurements is 
inherent with the mass measurement being per-
formed with an LTQ-FT mass spectrometer. Tan-
dem mass spectrometry (MS2) was performed 
on ion species m/z 742.04611 to generate 
the neutral loss species m/z 710.5 followed 
immediately by a second round of tandem 
mass spectrometry (MS3) on m/z 710.5. The 
resulting MS3 spectrum (C: split into 200–750 
and 750–1600 m/z panels for legibility) 
showed numerous diagnostic b- and y-type ions 
to identify the Cx43 peptide as tryptic peptide 
V347 to R366. The observed fragment ions 
were compared with the expected fragment 
ions (D) showing that the peptide contains a 
dehydroalanine (“A*”) at position 365 as a 
result of the neutral loss of phosphoric acid in 
the ﬁ   rst round of tandem mass spectrometry. 
The site of dehydroalanine reveals that S365 
as the site of phosphorylation within the pep-
tide (note: only the expected fragment ions 
that were observed in the MS3 spectrum are 
indicated in D).CX43 PHOSPHORYLATION AT S365 • SOLAN ET AL. 1303
localization at the intercalated disk and phosphorylation at S368 
increases (Ek-Vitorin et al., 2006). Western, immunoprecipita-
tion, and in vitro kinase studies show that effi  cient phosphoryla-
tion at S368 requires that S365 be unphosphorylated. We conclude 
that phosphorylation of Cx43 at S365 serves a “gatekeeper” 
function by causing a change in conformation that prevents PKC-
dependent phos  phorylation at S368 and subsequent changes in 
channel regulation.
Results
Determination of S365 as a site 
of phosphorylation in Cx43
Cx43 immunoprecipitated from confl  uent NRK cells was sepa-
rated by SDS-PAGE and the bands representing phosphorylated 
Cx43 were excised and subjected to mass spectrometry (MS) 
sequence analysis. Tryptic peptide analysis by LC MS/MS re-
vealed an ion species of m/z 742.04611 that was triply charged 
(Fig. 1 A, determined by the m/z difference of 0.333 between the 
isotopic peaks). A triply charged phosphorylated tryptic peptide 
of Cx43 with a m/z of 742.04645 would be predicted for the 
amino acids that span V347 to R366. Tandem mass spectrometry 
(MS2) of this ion species (Fig. 1 B) resulted in a spectrum domi-
nated by a single ion species of m/z 710.5 that corresponded to 
the loss of m/z 31.6, suggesting the neutral loss of phosphoric 
acid. The other ion species in the MS2 spectrum were of very 
low intensity, making it diffi  cult to interpret the amino acid 
sequence. A neutral-loss experiment was performed where ion 
species m/z 742.04611 was selected for MS2 and the resulting 
ion species m/z 710.5 was further selected for an additional 
round of fragmentation. The resulting MS3 spectrum (Fig. 1 C) 
showed abundant diagnostic fragment ions that verifi  ed the iden-
tity of the tryptic peptide V347-R366. Due to the neutral loss of 
a phosphate group, the phosphoserine would be converted to de-
hydroalanine. Analysis of the MS3 spectrum showed [y2]
1+ = 
244.7 and [y3]
1+ = 331.6, which locate the dehydroalanine to 
position 365 (Fig. 1 C). In summary, S365 in Cx43 was deter-
mined to be phosphorylated based on three results: (1) the high 
mass accuracy between the ion species that was measured and 
that was predicted for phosphorylated V347-R366; (2) the pro-
duction of a neutral-loss fragment during MS2 of V347-R366, 
indicating the loss of phosphoric acid; and (3) interpretation of 
an MS3 spectrum of the peptide undergoing neutral loss, indi-
cating dehydroalanine at amino acid 365.
Antibody validation by Western blot 
and immunoﬂ  uorescence
Because we found Cx43 to be signifi  cantly phosphorylated at 
S365, we prepared and immunoaffi  nity purifi  ed an antibody to 
Cx43 that only bound to S365 when it was phosphorylated (re-
ferred to as antibody pS365) by immunizing a rabbit with a syn-
thetic phosphopeptide representing amino acids 361–369 with 
S365 being phosphorylated. To determine the specifi  city of the 
antibody, we transfected MDCK cells that do not express Cx43 
(Jordan et al., 1999) with wild-type Cx43 or Cx43 containing the 
site-directed mutations S365A or S365D. After creation of stable 
lines by dilution cloning in antibiotic, we simultaneously probed 
an immunoblot that contained cell lysates from each line with 
both a mouse monoclonal antibody prepared to the N-terminal re-
gion of Cx43 (NT1) and the pS365 antibody using a fl  uorescence-
based co-labeling system. As shown in Fig. 2 A, the antibody to 
total Cx43 (NT1) bound to 41–44-kD (P0, P1, and P2) bands in 
the lane containing the lysate from wild-type cells (WT). The 
S365A cells exhibited the P0, P2, and a faint band intermediate 
between P0 and P1, but not a distinct P1 isoform. The S365D cells 
exhibited multiple faint bands migrating between P0 and P1. 
When the pS365 antibody labeling was examined in the other 
fl  uorescence channel, signal was only detected in the WT lane with 
a distinct prominent bands at P1and P2 as shown in the pS365 
panel and in the overlay panel (NT1 [red] + pS365 [green]) of 
Fig. 2 A. Fig. 2 B shows co-labeled immunofl  uorescence of pS365 
(top) and total Cx43 (bottom) in MDCK cells expressing wild-
type, S365A, or S365D Cx43. The pS365 antibody only showed 
labeling of the WT-expressing cells, mostly at apparent junctional 
structures, whereas mutation to A or D eliminated pS365 labeling. 
Figure 2.  pS365 is speciﬁ  c for Cx43 phosphorylated on S365, recognizes 
predominantly the P1 isoform of Cx43 and is found in apparent gap junc-
tion plaques. (A) Western blot analysis of lysates from stably transfected 
MDCK cells, expressing wild type (WT), S365A or S365D mutant Cx43, 
were probed for total Cx43 (NT1) and with a polyclonal antibody gener-
ated to recognize Cx43 phosphorylated at S365. The phospho-antibody 
recognizes Cx43 in WT-expressing cells, but not when S365 is converted 
to alanine or aspartate. The faint bands in the 50–54-kD range are visible 
with multiple Cx43 antibodies, but we have been unable to identify the 
modiﬁ  cation that leads to this migration shift. Overlay of NT1 (red) and 
pS365 (green) signals show that they are coincident. Densitometry on the 
individual isoforms (isoform density) shows that pS365 signal is highest in 
the P1 and P2 isoforms. The migration positions of molecular weight stan-
dards are indicated on the left in kD. (B) Immunoﬂ  uorescence using pS365 
and a monoclonal antibody for total Cx43 shows that pS365 resides pre-
dominantly in the plasma membrane (WT Cx43) and that the pS365 epi-
tope is eliminated by conversion from serine to alanine or aspartate 
(S365A, S365D) (bar = 25 μm).JCB • VOLUME 179 • NUMBER 6 • 2007  1304
The antibody to total Cx43 immunolabeled both apparent punc-
tate junctional structures at cell–cell interfaces and cytoplasmic 
membranes in all three transfectants. Note that the pS365 anti-
body only labels a subset of the punctate gap junctional structures 
observed with the total Cx43 antibody and none of the cytoplas-
mic Cx43. The fact that mutation of S365 to A or D does not ap-
pear to affect the ability of Cx43 to transport to the membrane 
indicates that this phosphorylation event is probably not essential 
for gap junction assembly. We also performed dye microinjection 
experiments to see if the S365A mutant cells could participate in 
gap junctional communication. When the number of cells that 
received dye per microinjected cell was determined for S365A 
(31.6 ± 7.0; mean ± SEM) and wild-type Cx43 (30.7 ± 3.5) ex-
pressing clones, no statistical difference was observed.
Phosphorylation on S365 creates 
the P1 isoform
To study the role of S365 phosphorylation on the migratory iso-
types of Cx43, we examined multiple clones of MDCK cell 
lines expressing Cx43 WT, S365A, and S365D. Because S365 
is part of a diserine repeat (S364/S365) and S364 can be phos-
phorylated (TenBroek et al., 2001), we also examined how S364 
affected Cx43 migration. When lysates from two separate clones 
for each Cx43 construct were examined by Western blot for to-
tal Cx43, we found that both S365 mutant clones made predom-
inantly P0 and that neither made the P1 isoform of Cx43 (Fig. 3, 
NT1 panel). Even when the S365A clone was heavily over-
loaded relative to the wild type, no P1 was observed (Fig. 3, 
right panels). Although the S364A-containing cells made rela-
tively more P0 than the wild type, they were capable of making 
the P1 and P2 isoforms (Fig. 3). We also examined these cells 
using an antibody generated in our lab, Cx43CT1 (CT1), which 
we have epitope mapped and found to be specifi  c for Cx43 that 
is not phosphorylated at S364 or S365 (Sosinsky et al., 2007). 
Figure 3.  Mutation of S365 eliminates the P1 isoform of Cx43. Lysates 
from two separate stable cell lines expressing wild type (WT), S365A, 
S365D or S364A mutant Cx43 were probed for total Cx43 (NT1) and 
with an antibody that recognizes Cx43 containing unmodiﬁ  ed S364 and 
S365 (CT1). WT and S364A make all three Cx43 isoforms, while neither 
S365A nor S365D make the P1 isoform. The two tick marks on the right 
side of the left panel indicate the position of 50- and 36-kD standards. 
The right panels show a comparison of WT and S365A Cx43 expressing 
cells with the latter being overloaded to show a lack of the P1 isoform.
Figure 4.  NMR conformational analysis of wild-type and S365D mutant Cx43CT. 
15N-HSQC spectra for wild-type Cx43CT (black) and S365D mutant (red) 
are presented in A (pH 5.8) and B (pH 7.5). C shows a close-up view of resonance peaks from A and B to illustrate residues that had clearly shifted at both 
pH 5.8 and 7.5 (top), that only shifted at pH 5.8 (middle), and that only shifted at pH 7.5 (bottom). D provides a summary of the residues affected by the 
S365D substitution at pH 5.8 and 7.5. The model and 
15N-HSQC spectra are encoded as follows: blue, common changes between pH 5.8 and 7.5, yellow, 
S365D point mutant; green, regions different between the two pHs; black line, helical domains (invariant between the two pHs); red line, residues affected 
by the ZO-1 PDZ-2 domain; and gray boxes, residues affected by the Cx43 cytoplasmic loop domain. CX43 PHOSPHORYLATION AT S365 • SOLAN ET AL. 1305
When this antibody is used to detect wild-type Cx43, we fi  nd 
that it does not recognize the P1 isoform of Cx43 (Fig. 3, CT1 
panel), but it often recognizes a faint band that is an apparent 
subset of the P2 form. Note that this is consistent with the ability 
of the S365A and S365D mutants to make some P2. Mutation of 
either S364 or S365 ablated the ability of the CT1 antibody to 
recognize Cx43 (Fig. 3, CT1 panel), indicating that the serines 
themselves are important in creating the conformational epitope 
recognized by this antibody.
The structure of Cx43CT wild type vs. 
S365D mutant via NMR
We have recently used a combination of nuclear magnetic reso-
nance (NMR) and mirror resonance technology to characterize 
the structure of the CT of Cx43 (Cx43CT) and assign backbone 
and side chain resonance values for most of the residues from 
255–382 (Duffy et al., 2002; Sorgen et al., 2004b). These studies 
indicated a pH-dependent shift in the ability of Cx43CT to inter-
act with itself, with the cytoplasmic loop of Cx43, and other 
interacting proteins (Duffy et al., 2002; Sorgen et al., 2002, 
2004a,b). Here, we used similar 
15N-heteronuclear single-quantum 
correlation (HSQC) experiments to compare the structure of 
wild-type and a mutant version of Cx43CT that only varied by 
the substitution of S365 with aspartic acid to mimic phosphory-
lation at that site (Fig. 4). The 
15N-HSQC is a two-dimensional 
NMR experiment in which each amino acid (except proline) 
gives one signal (or chemical shift) that corresponds to the N–H 
amide group. These chemical shifts are sensitive to the chemical 
environment, and even small changes in structure and/or dynam-
ics can change the chemical shift of an amino acid. At pH 5.8, 
this substitution (Fig. 4 A, yellow) affected the resonance peaks 
of residues T275-A276, G285-Y286, L356-S368, and R370-
D379 (shown in blue, except D378 and D379 [green]). A blown-
up view shows the extensive shifts of D360 and A367/A371 
(Fig. 4 C, top left) and D378 (middle left). At pH 7.5, T275-
A276, G285-K287, L356-S368, and R370-R376 also showed 
different resonance values between the wild-type and S365D 
mutant. Although most of these shifts were very comparable to 
pH 5.8 values, K287 changes at pH 7.5 but D378-D379 does not 
(areas highlighted in green in A and B, and their difference em-
phasized in the bottom four sections of C). In general, the resi-
dues closer to the mutation had dramatic shifts, indicating the 
formation of a stable conformation different than the wild type, 
while the others were more subtle. We conclude that the S365D 
mutation has a dramatic effect on the structure at either pH with 
slight differences between the two.
S365 is constitutively phosphorylated 
in heart and becomes dephosphorylated 
during hypoxia
We examined S365 phosphorylation using a model of ischemia 
in mouse heart. Cx43 in normal heart is concentrated in gap 
junction plaques at the intercalated disk (Fig. 5), as has been 
shown in numerous other studies (Jain et al., 2003; Schulz et al., 
2003). When hypoxia is induced, Cx43 is redistributed to the 
lateral edges so that it is no longer concentrated at the interca-
lated disk (Fig. 5; Beardslee et al., 2000; Schulz et al., 2003; 
Ek-Vitorin et al., 2006). We examined Cx43 phosphorylation at 
S365, as detected with the pS365 antibody, in heart before and 
after hypoxia. The pS365 antibody showed extensive labeling at 
the intercalated disk in control heart that was lost upon hypoxia. 
We have previously reported that phosphorylation on S368 was 
actually increased during hypoxia (Ek-Vitorin et al., 2006), as 
also shown in Fig. 5 (bottom panels). Analysis of 8 fi  elds of 
heart tissue for each condition indicated a 1.8-fold increase in 
pS368 staining at intercalated disk upon hypoxia that was statis-
tically different from the control (P = 0.04). Because dephos-
phorylation is a key event during ischemia, we investigated the 
potentially antagonistic relationship between phosphorylation at 
S365 and S368.
Phosphorylation at S365 prevents 
phosphorylation at S368
Treatment of cells with phorbol esters has been shown to in-
crease the phosphorylation of Cx43 at S368 (Lampe et al., 2000; 
Figure 5.  Differential phosphorylation of Cx43 localized at intercalated 
disks vs. lateral edges of myocytes in the normoxic and ischemic heart. 
The localization of total Cx43, pS65-Cx43, and pS368 in normoxic and 
hypoxic heart is shown. Note the increase in total Cx43 at the lateral 
edges of the myocytes and loss from the intercalated disk of the ischemic 
heart. Cx43 was not detectably phosphorylated at S365 in the hypoxic 
heart, but phosphorylation at S368 was increased mainly in the interca-
lated disk region (bar = 20 μm). JCB • VOLUME 179 • NUMBER 6 • 2007  1306
Solan et al., 2003), so MDCK cells expressing wild-type (WT), 
S365A, or S365D Cx43 were treated with PMA to examine 
phosphorylation levels at S368 compared with control levels. 
We found that control levels of pS368 antibody binding were 
similar between WT and S365A-expressing cells, but pS368 
levels were reduced in S365D cells (Fig. 6). Furthermore, PMA 
treatment led to more than a two- and three-fold increase in 
S368 phosphorylation in the WT and S365A cells, respectively, 
whereas there was only a 0.3-fold increase in S365D cells. 
These results indicate that having a negative charge at S365 in-
hibited phosphorylation at S368 and mutation of S365 to a neu-
tral, nonphosphorylatable residue increased the ability of PMA 
to stimulate phosphorylation at S368. However, these results 
cannot defi  nitively argue the interdependence of the phosphory-
lation events because conversion to D does not exactly replicate 
addition of a phosphate, and a low level of phosphorylation at 
S368 was detected in the S365D mutant.
To further address this question, we looked specifi  cally at 
these Cx43 phosphoforms, using NRK cells that endogenously 
express Cx43. Immunoprecipitations were performed using 
three different polyclonal antibodies, pS365, pS368, and an 
anti-Cx43 antibody (α-Cx43) that recognizes all three isoforms 
of Cx43. Western blots of these lysates were simultaneously 
probed with monoclonal NT1 (Fig. 7 A, top) and pS368 (Fig. 7 A, 
bottom) and detected in separate channels. Note that pS365 
antibody immunoprecipitated predominantly the P1 and P2 iso-
forms, but a small fraction of immunoprecipitated Cx43 mi-
grated at P0 or between P0 and P1. The pS365 antibody could 
be slightly less specifi  c under immunoprecipitation conditions. 
However, it is also possible that some dephosphorylation occurs 
during the immunoprecipitation protocol, leading to the minor 
amounts of apparent P0 after SDS-PAGE. In both the cell lysate 
and α-Cx43 immunoprecipitate, pS368 was detectable mostly 
in the PMA-treated cells (PMA+), migrating primarily at the 
P0 position and nearly absent from control cells (PMA−). 
When expressed as pS368 signal over NT1 signal (Fig. 7 B), a 
3–4.3-fold increase was observed upon PMA treatment for cell 
lysates and lysates immunoprecipitated with α-Cx43 or pS368. 
Cell lysates immunoprecipitated with pS365 showed little pS368 
or P0 regardless of treatment, and these values were statisti-
cally different than those for both the α-Cx43 or pS368 immuno-
precipitates (P < 0.01), consistent with phosphorylation of 
S365 preventing phosphorylation on S368. Collectively, these 
mutant and immunoprecipitation data indicate that phos-
phorylation at S365 prevents phosphorylation at S368 in re-
sponse to PMA.
PMA increases PKC activity and PKC has been shown to 
phosphorylate Cx43 at S368 in vitro (Saez et al., 1997; Lampe 
et al., 2000). Therefore, we wanted to see if a negative charge at 
S365 directly inhibited the ability of PKC to phosphorylate 
Cx43. Wild-type and S365D GST-Cx43CT fusion proteins were 
phosphorylated with PKC and probed with the pS368 antibody. 
The wild-type version of the protein was effi  ciently phosphory-
lated, whereas the mutant was not, as shown in Fig. 8 A. To be 
more quantitative about the difference and to ensure that the 
 affi  nity of the pS368 antibody was not affected by the mutation 
at S365, we also performed the reaction with γ-[
32P]ATP. Auto-
radiography (Fig. 8 B) and excision of the bands and scintilla-
tion counting indicated that PKC phosphorylated the wild type 
4.3-fold more effi  ciently than the S365 Cx43CT (n = 4, signifi  -
cant at P < 0.0001). We conclude that phosphorylation at 
S365 dramatically reduces the effi  ciency of PKC-dependent 
phosphorylation at S368.
Discussion
In this manuscript, we have presented the following evidence 
that phosphorylation of Cx43 at S365 is a key regulatory event: 
Cx43 is phosphorylated on S365 in homeostatic cells. NMR 
structural studies of the C-terminal region of Cx43 with a S365D 
mutation indicate that it forms a different stable conformation 
Figure 6.  Conversion of S365 to alanine enhances, while aspartate 
  inhibits PMA-activated phosphorylation of S368. (A) Western blot of cell 
lysates from wild-type Cx43 (WT), S365A, and S365D cells treated with 
100 nM PMA for 30 min (PMA) or not (CON) were probed for total Cx43 
(NT1) and Cx43 phosphorylated on S368 (pS368). The migration posi-
tions of molecular weight standards are indicated on the right in kD. 
(B) Signals were quantiﬁ  ed and expressed as a ratio of pS368 over NT1. 
Shown are results of three experiments using three separate clones (nine 
total measurements) for each construct. Values were normalized to control 
for each clone and error bars represent SEM. Western blot is representa-
tive, showing a single clone for each construct.
Figure 7.  Cx43 phosphorylated on S365 is not phosphorylated on S368. 
(A) Western blot of Cx43 immunoprecipitated from NRK cells treated with 
100 nM PMA for 30 min (+) or untreated (−). Cx43 from lysates or Cx43 
immunoprecipitated from cell lysates using antibodies to total Cx43 
(α-Cx43), pS365, or pS368 were probed for total Cx43 (NT1, top) and 
Cx43 phosphorylated on S368 (pS368, bottom). The two tick marks on the 
right side indicate the position of 50- and 36-kD standards. (B) Signals 
were quantiﬁ  ed and expressed as a ratio of pS368 over NT1 normalized 
to a value of 1 for the untreated sample immunoprecipitated and immuno-
blotted for pS368 to allow comparison for ﬁ  ve separate experiments 
(mean ± SEM).CX43 PHOSPHORYLATION AT S365 • SOLAN ET AL. 1307
than unphosphorylated wild type Cx43. An antibody specifi  c 
for Cx43 only when it is phosphorylated at S365 showed that 
this phosphorylation event occurs on Cx43 present in gap 
junction structures and in heart tissue at intercalated disks. 
Phosphorylation at S365 was constitutive in heart tissue and lost 
upon hypoxia when the specifi  c localization of Cx43 to the 
  intercalated disk was also lost. Phosphorylation at S368, on the 
other hand, increased in heart upon 30 min of hypoxia. Phos-
phorylation at S368 was dramatically reduced when S365 was 
phosphorylated arguing that S365 dephosphorylation likely 
precedes S368 phosphorylation during hypoxia. PKC-dependent 
phosphorylation of S368 was dramatically reduced by mimic-
king phosphorylation at S365 with a S365D mutation. We con-
clude that phosphorylation of Cx43 at S365 serves a gatekeeper 
function by causing a change in conformation that allows main-
tenance of gap junctional communication.
We also present evidence that S365 phosphorylation is 
necessary for the full SDS-PAGE migration shift from P0 to P1: 
S365A mutants are not capable of making the P1 isoform 
(Figs. 2 and 3). The CT1 antibody, which we have epitope mapped 
to unphosphorylated S364/S365 (Sosinsky et al., 2007), does 
not recognize P1 or the S365A and S365D mutants (Fig. 3). 
Our pS365 antibody has a strong preference for the P1 and P2 
isoforms, especially in a Western assay but also upon immuno-
precipitation (Figs. 2 and 7). The pS365 antibody binds only to 
junctional Cx43 in immunofl  uorescence (Figs. 2 and 5). The 
S365D mutation leads to a discernable conformational change 
by NMR (Fig. 4); because addition of phosphate (i.e., 80 D) 
cannot account for the 2–3-kD apparent shift in molecular weight 
observed between P0 and P1, the conformational change could 
be responsible for the shift. Other phosphorylation events may 
also play a role in the shift, but we conclude that phosphory-
lation at S365 is necessary.
Phosphorylation of Cx43 at S364, S365, S368, S369, and 
S373 has been reported in response to increased cAMP levels   
(TenBroek et al., 2001; Yogo et al., 2002, 2006). In this paper, 
we found that phosphorylation at S365 occurred in homeostatic 
cells. Thus, we consider phosphorylation on S365 a “constitu-
tive” event in the Cx43 “life cycle”. We were surprised that sub-
stitution of S365 with aspartic acid had such dramatic effects 
on the solution structure of the C-terminal region of Cx43. 
Not only were residues L356-D379 affected, but 275-A276 and 
G285-Y286—almost 100 residues upstream—were also affected. 
We can only speculate that the C-terminal region interacts with 
residues in the 275–286 range, affecting its structure. Interest-
ingly, some of the Cx43CT residues affected by the S365D 
substitution overlap with the residues previously identifi  ed to be 
affected by the interaction with the Cx43 cytoplasmic loop and 
the ZO-1 PDZ-2 domains (Sorgen et al., 2004a), which suggests 
the binding affi  nity of both domains may be affected by S365 
phosphorylation.
In heart, Cx43 is localized to intercalated disks where it 
supports the longitudinal and transverse spread of the action 
potential, resulting in coordinated contraction. Myocardial 
ischemia/hypoxia leads to Cx43 dephosphorylation and loss of 
Cx43 localization to the intercalated disk, which likely contrib-
utes to apoptosis, contractile failure, and arrhythmias (Beardslee 
et al., 2000; Schulz et al., 2003). Ischemic preconditioning, or 
exposure of the heart to a brief period(s) of ischemia (e.g., 2–5 min) 
followed by reperfusion, before a more prolonged ischemic 
period (i.e., 30 min or more) protects the heart against necrosis 
and fatal arrhythmias (Cohen et al., 2000; Jain et al., 2003; 
Schulz et al., 2003). PKC is activated during preconditioning 
and appears to be necessary for protection against injury during 
the subsequent prolonged ischemic period. Because cardiac 
ischemia/hypoxia causes PKC activation, unidentifi  ed Cx43 de-
phosphorylation events, Cx43 relocalization (Beardslee et al., 
2000; Schulz et al., 2003), and PKC-dependent phosphorylation 
of Cx43 at S368, the interrelationship of Cx43 phosphorylation 
at S365 and S368 will likely prove to be important in ischemia 
and preconditioning. Furthermore, because phosphorylation at 
S368 is regulated by tumor promoting agents, is controlled dur-
ing the cell cycle, and is developmentally regulated (Lampe 
et al., 2000; Solan et al., 2003; King and Lampe, 2005), this 
gatekeeper role for S365 phosphorylation may be critical for 
growth control.
Materials and methods
Antibodies, cDNA constructs, and other reagents
All general chemicals, unless otherwise noted, were purchased from Fisher 
Scientiﬁ  c. Mouse anti-Cx43 antibodies, Cx43CT1 and Cx43IF1, were pre-
pared against amino acids 360–382 of Cx43 and antibody Cx43NT1 
against amino acids 1–20 (Cx43NT1) of Cx43 (described in Cooper and 
Lampe, 2002; Lampe et al., 2006; Sosinsky et al., 2007) at the Fred 
Hutchinson Cancer Research Center Hybridoma Development Facility 
(Seattle, WA). The pS368 antibody was custom prepared and afﬁ  nity puriﬁ  ed 
by 21st Century Biochemicals. A rabbit antibody against Cx43 was pur-
chased from Sigma-Aldrich and a similar rabbit antibody (α-Cx43) pro-
duced to the peptide representing A367-I382 of Cx43 was a gift of Alton 
Boynton (Northwest Biotherapeutics, Bothell, WA; Hossain et al., 1998). 
We made a rabbit anti-pS365-Cx43 antibody by custom commercial prep-
aration (ProSci, Inc.; 13-wk schedule) against a synthetic peptide that was 
phosphorylated at S365 (CQRPS(pS)RASS-amide) and that we linked via 
the N-terminal cysteine to maleimide-activated KLH (Pierce Chemical Co.) 
according to manufacturer’s instructions. Phosphospeciﬁ  c antibody was 
  afﬁ  nity puriﬁ  ed essentially identically to our previously published method 
(Lampe et al., 2006). In brief, this involved passing the serum ﬁ  rst over a 
column prepared with the nonphosphorylated peptide, followed by a phos-
phopeptide column and elution of the phosphospeciﬁ  c antibody.
Figure 8.  PKC can efﬁ  ciently phosphorylate wild type, but not the S365D 
mutant Cx43. PKC was used to phosphorylate wild-type (WT) and S365D 
mutant GST-Cx43CT in vitro and the proteins were separated by SDS-
PAGE. (A) The level of S368 phosphorylation was determined in a Western 
blot with pS368 antibody (WB:pS368) and consistent loading was shown 
with an antibody to GST (WB:GST). The migration positions of molecular 
weight standards are indicated on the left in kD. (B) The level of phosphoryl-
ation was determined directly by incorporation of 
32P from radiolabeled 
ATP and autoradiography (
32P panel). Consistent loading is shown in the 
panel showing the Coomassie blue–stained gel (CB panel).JCB • VOLUME 179 • NUMBER 6 • 2007  1308
Serine-to-alanine mutations at S364 and S365 were made using the 
GeneTailor site-directed mutagenesis system (Invitrogen) on full-length Cx43 
that had been cloned into the mammalian expression vector pIREShyg 
(Clonetech Laboratories, Inc.). A serine-to-aspartic acid mutation at S365 
was similarly performed on GST-Cx43CT (the C-terminal region of Cx43, 
amino acids 255–382 linked to the C terminus of GST), and the wild-type 
and mutant protein were expressed and puriﬁ  ed as previously described 
for the wild-type version (Duffy et al., 2002).
Cell line maintenance and transfection
NRK-E51 (American Tissue Culture Collection; Manassas, VA) and MDCK 
cells were cultured in DME (Mediatech) supplemented with 10% FBS and 
antibiotics in a humidiﬁ  ed 5% CO2 environment. Wild-type and mutant 
Cx43 were electroporated into the MDCK cell lines via a Nucleofector ap-
paratus (Amaxa Biosystems). Stably transfected clones were isolated with 
cloning rings and selected with hygromycin (200 μg/ml).
Identiﬁ  cation of S365 as a phosphorylated residue
Ten 150-cm plates of NRK cells were grown to conﬂ  uency and lysed in PBS 
containing phosphatase/protease inhibitors (50 mM NaF, 500 μM 
Na3VO4, 2 mM PMSF, 1× Roche Complete protease inhibitors) and 1% 
Triton X-100. After centrifugation at 30,000 g for 30 min at 4°C, the pellet 
was resuspended in RIPA buffer (25 mM Tris-HCl, 100 mM NaCl, 10 mM 
EDTA, and protease/phosphatase inihibitors) containing 0.5% Triton 
X-100, 0.5% sodium deoxycholate, and 0.1% SDS, and pre-cleared with 
protein A beads. Cx43 was immunoprecipitated with monoclonal Cx43CT1 
and Cx43IF1 antibodies using protein A beads. The immunoprecipitate 
was subjected to SDS-PAGE (10% polyacrylamide) and protein bands 
were silver stained. Bands corresponding to phosphorylated Cx43 were 
excised from the gel and the silver stain was removed by incubation with 
equal volumes of 30 mM K4Fe(CN)6 and 100 mM Na2S2O3 for 5 min, fol-
lowed by several washes with 100 mM NH4CO3 until the gel slices were 
clear. Destained gel slices were subjected to in-gel tryptic digestion as 
  previously described (Shevchenko et al., 1996) and the resulting peptide 
mixtures were desalted using a microC18 ZipTip and taken to dryness. 
Samples were then resuspended in 5 μl of 0.1% formic acid and analyzed 
by liquid chromatography coupled to electrospray ionization tandem mass 
spectrometry (LC/ESI MS/MS) with a nano2D LC (Eksigent Technologies) 
coupled to an LTQ-FT mass spectrometer (ThermoElectron Corporation) as 
previously described (Yi et al., 2003). Data were collected in a data-
dependent mode in which a high mass resolution/high mass accuracy scan 
(in the FT part of the instrument) was followed by low resolution/low mass 
accuracy MS/MS scans (in the LTQ part of the instrument) of the three most 
abundant ions from the preceding MS scan. The FT part of the instrument 
was set at a target resolution of 100,000 at m/z 400, an AGC target 
value of 1e6, and a maximum ion time of 1,500 ms, while the ion trap was 
set to a MSn AGC target value of 1e4 and a MSn maximum ion time of 
100 ms. The data-dependent method triggered a MS3 (MS/MS/MS) anal-
ysis on a MS2 (MS/MS) ion species if a MS2 ion species differed from the 
precursor ion species by m/z 98.0, 49.0, or 32.7, the neutral loss of 
phosphoric acid for a singly, doubly, or triply charged ion species, respec-
tively. Normalized collision energy of 35% and isolation widths of 2.0 
were used for both MS2 and MS3 events. Dynamic exclusion was enabled 
with a repeat count of 2, a repeat duration of 30 s, an exclusion duration 
of 60 s, and an exclusion mass width of 1.5.
Immunoblotting and immunoprecipitation
For whole cell extracts, cells were lysed in sample buffer containing 50 mM 
NaF, 500 μM Na3VO4, 2 mM PMSF, and 1× Complete protease inhibitor 
(Roche), and cellular proteins were separated by SDS-PAGE (10% poly-
acrylamide). For immunoprecipitation, cells were rinsed in PBS and lysed 
on ice in RIPA buffer (25 mM Tris-HCl, 100 mM NaCl, 10 mM EDTA, 
50 mM NaF, 500 μM Na3VO4, 0.5% Triton X-100, 0.5% deoxycholate, 
2 mM PMSF, and 1× Complete protease inhibitors). Cx43 was immuno-
precipitated using pS365, pS368, and α-Cx43 antibodies by incubation with 
cell lysate for 2 h, followed by incubation with protein A for 1 h at 4°C. 
After several washes in RIPA buffer, Cx43 was eluted in 2× Laemmli sample 
buffer and separated by SDS-PAGE. Protein was transferred to nitrocellu-
lose, the membrane was blocked, and antibodies were incubated as previ-
ously indicated (Lampe et al., 2006). pS365 and pS368 were detected 
with AlexaFluor 680 or IRDye800 anti–rabbit antibody, CT1 antibody 
(IgG2a) with ﬂ  uorescent dye-labeled isotype speciﬁ  c secondary antibody 
(AlexaFluor680 goat anti–mouse IgG2a (Molecular Probes, Inc.), and NT1 
(IgG1) with IRDye800 donkey anti–mouse IgG1 (Rockland Immunochemicals) 
(all extensively cross-reacted against other species) and directly quantiﬁ  ed 
using the Li-Cor Biosciences Odyssey infrared imaging system and associ-
ated software. Images were converted from16-bit to 8-bit images after 
maximizing the dynamic range of pixel intensity using the “Levels” function 
in Adobe Photoshop. Most images (except Fig. 2 A overlay) were inverted to 
present them in the conventional black-on-white manner.
Immunoﬂ  uorescence and immunostaining
Cells were washed twice in PBS, ﬁ  xed in cold methanol/acetone (50:50) 
for 1 min, and blocked for 1 h in 1% BSA in PBS. Cells were incubated 
with anti-Cx43 antibody (pS365 antibody, Cx43CT1, and/or Cx43IF1) in 
blocking solution for 1 h. After several PBS washes, the cultures were 
  incubated with Alexa 594–conjugated goat anti–rabbit antibody and/or 
Alexa 488–conjugated goat anti–mouse antibody for 30–60 min and 
counterstained with DAPI (Molecular Probes), followed by several washes 
in PBS. The coverslips were mounted onto slides with DABCO anti-fade 
medium (25 mg/ml of 1,4-Diazobicyclo-(2,2,2)octane [Sigma-Aldrich] di-
luted in Spectroglycerol [Kodak] and 10% PBS, pH 8.6) and viewed with 
a Nikon Diaphot TE300 ﬂ  uorescence microscope, equipped with a 40× 
(1.3 NA) Plan Fluor oil objective; images were collected with a Princeton 
Instruments −20°C cooled digital camera driven by an attached PC and 
MetaMorph imaging software.
Immunohistochemistry
All mouse studies were conducted under Institutional Animal Care and Use 
Committee approval (FHCRC). Inbred mice (4 mo of age in a FVB/N:
C57BL6 background) were anaesthetized (avertin, 0.83 mg/g body 
weight), hearts excised and placed either in cold PBS (with 1.8 mmol/L 
calcium, glucose free) for 30–60 s (control group) or incubated without 
coronary perfusion in warm (37°C), non-oxygenated PBS for 30 min 
(“hypoxia group”) (Ek-Vitorin et al., 2006). Formalin-ﬁ  xed heart tissue was 
processed, sectioned, immunostained, and microscopically analyzed as 
previously described (King and Lampe, 2004). In brief, tissue sections 
were deparafﬁ  nized, antigen retrieved, blocked, and detected using rabbit 
anti-Cx43, pS365, or pS368. Slides were washed and incubated with a 
biotinylated anti–rabbit secondary antibody (1:250) and detected with 
ABC-avidin/biotin conjugate (Vectastain; Vector Laboratories). 24-bit color 
images were collected using a Nikon Coolpix 990 digital camera attached 
to a Nikon Eclipse E400 microscope equipped with a 10× Plan Fluor ob-
jective (0.3 NA). We quantiﬁ  ed the extent of pS368 staining at interca-
lated discs in control and hypoxic heart sections using MetaMorph 7.0 
(Molecular Devices). Using the “Set Color Threshold” function, we selected 
the pS368 staining using the “Set by Example” function. The same Thresh-
old values were used for all images analyzed. The integrated intensity of 
the thresholded pixels was measured. This value was normalized to the 
total area of tissue in each image. The area was determined by drawing a 
region around the tissue and measuring within this region. Eight images 
were analyzed per condition and a two-sided t test was performed.
Nuclear magnetic resonance
NMR data were acquired at 7°C using a 600-MHz Varian INOVA NMR 
spectrometer ﬁ  tted with a cryoprobe at the University of Nebraska Medical 
Center’s NMR Shared Resource Facility. Gradient-enhanced two-dimensional 
15N-HSQC experiments (Kay et al., 1992) were used to observe all back-
bone amide resonances in 
15N-labeled Cx43CT wild-type and S365D mu-
tant Cx43CT. Data were acquired with 1024 complex points in the direct 
dimension and 128 complex points in the indirect dimension. Sweep widths 
were 10,000 Hz in the proton dimension and 2,500 Hz in the nitrogen 
  dimension. NMR spectra were processed using NMRPipe (Delaglio et al., 
1995) and analyzed using NMRView (Johnson and Blevins, 1994).
In vitro phosphorylation
Wild-type or S365D mutant GST-Cx43CT attached to glutathione beads 
was phosphorylated with 10 units of PKC (Phospho Solutions) in 10 mM 
MgCl2, 50 mM NaCl, 40 mM Tris-HCl, pH 7.5, and 100 μM γ-[
32P]ATP 
(BLU002; Perkin Elmer) for 10 min. After three washes in PBS, sample buf-
fer including 5% β-mercaptoethanol was added, samples were separated 
by SDS-PAGE, and the gel was stained with Coomassie blue. The stained 
gel was scanned in the Li-Cor scanner to determine protein loads, sub-
jected to autoradiography using Hyperﬁ  lm (Amersham Biosciences), and 
the bands were subsequently excised to allow the radioactivity to be 
quantiﬁ  ed in a scintillation counter (Beckman Coulter) and a two-sided 
t test was performed.
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